Business Description
Elicera Therapeutics AB
ISIN : SE0015382080
Share Class Description:
FRA:8E8: Ordinary SharesCompare
Compare
Traded in other countries / regions
ELIC.Sweden8E8.Germany IPO Date
2021-06-30Description
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.77 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -75.8 | |||||
| 3-Year EPS without NRI Growth Rate | -76.1 | |||||
| 3-Year FCF Growth Rate | -144 | |||||
| 3-Year Book Growth Rate | 1.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.49 | |||||
| 9-Day RSI | 46.85 | |||||
| 14-Day RSI | 48.61 | |||||
| 6-1 Month Momentum % | 190.38 | |||||
| 12-1 Month Momentum % | -62.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.25 | |||||
| Quick Ratio | 4.25 | |||||
| Cash Ratio | 4.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.2 | |||||
| Shareholder Yield % | -31.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -89.41 | |||||
| ROA % | -59.52 | |||||
| ROIC % | -243.3 | |||||
| ROCE % | -85.3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.52 | |||||
| Price-to-Tangible-Book | 2.51 | |||||
| EV-to-EBIT | -1.25 | |||||
| EV-to-Forward-EBIT | -0.09 | |||||
| EV-to-EBITDA | -1.25 | |||||
| EV-to-Forward-EBITDA | -0.09 | |||||
| EV-to-Forward-Revenue | 4.69 | |||||
| EV-to-FCF | -1.17 | |||||
| Price-to-Net-Current-Asset-Value | 2.51 | |||||
| Price-to-Net-Cash | 2.51 | |||||
| Earnings Yield (Greenblatt) % | -80.99 | |||||
| FCF Yield % | -47.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Elicera Therapeutics AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.08 | ||
| Beta | -0.4 | ||
| Volatility % | 151.93 | ||
| 14-Day RSI | 48.61 | ||
| 14-Day ATR (€) | 0.006666 | ||
| 20-Day SMA (€) | 0.130975 | ||
| 12-1 Month Momentum % | -62.16 | ||
| 52-Week Range (€) | 0.047 - 0.466 | ||
| Shares Outstanding (Mil) | 35.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Elicera Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Elicera Therapeutics AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Elicera Therapeutics AB Frequently Asked Questions
What is Elicera Therapeutics AB(FRA:8E8)'s stock price today?
The current price of FRA:8E8 is €0.13. The 52 week high of FRA:8E8 is €0.47 and 52 week low is €0.05.
When is next earnings date of Elicera Therapeutics AB(FRA:8E8)?
The next earnings date of Elicera Therapeutics AB(FRA:8E8) is 2025-02-13.
Does Elicera Therapeutics AB(FRA:8E8) pay dividends? If so, how much?
Elicera Therapeutics AB(FRA:8E8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers